Muscular Dystrophy: Multi-National And Multi-Site Trials

ReveraGen BioPharma, a US-based drug development company specializing in rare diseases like Duchenne Muscular Dystrophy (DMD), partnered with Due to Novotech’s reliable performance in the past, ReveraGen expanded their partnership to a larger phase 2b trial (VBP15-004). The DMD phase 2b trial aimed to secure FDA approval for vamorolone by evaluating its safety, tolerability, and efficacy against a placebo across 32 sites in 11 countries. Despite the trial being conducted amid the COVID-19 pandemic, ReveraGen expressed high satisfaction with Novotech’s expertise and ability to consistently meet expectations, emphasizing the CRO's essential role in executing complex trials.